JP7684047B2 - インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 - Google Patents

インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 Download PDF

Info

Publication number
JP7684047B2
JP7684047B2 JP2020560958A JP2020560958A JP7684047B2 JP 7684047 B2 JP7684047 B2 JP 7684047B2 JP 2020560958 A JP2020560958 A JP 2020560958A JP 2020560958 A JP2020560958 A JP 2020560958A JP 7684047 B2 JP7684047 B2 JP 7684047B2
Authority
JP
Japan
Prior art keywords
fusion protein
structural unit
subunit
linker segment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522786A5 (enExample
JP2021522786A (ja
Inventor
フー，ヤン－シン
ペン，フア
グオ，ジンヤ
Original Assignee
イミューン ターゲティング インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューン ターゲティング インク． filed Critical イミューン ターゲティング インク．
Publication of JP2021522786A publication Critical patent/JP2021522786A/ja
Publication of JP2021522786A5 publication Critical patent/JP2021522786A5/ja
Priority to JP2025082038A priority Critical patent/JP2025124695A/ja
Application granted granted Critical
Publication of JP7684047B2 publication Critical patent/JP7684047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2020560958A 2018-05-04 2019-05-03 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 Active JP7684047B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025082038A JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810420739.6A CN110437339B (zh) 2018-05-04 2018-05-04 一种以白介素15为活性成分的融合蛋白型药物前体
CN201810420739.6 2018-05-04
PCT/US2019/030594 WO2019213517A1 (en) 2018-05-04 2019-05-03 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025082038A Division JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Publications (3)

Publication Number Publication Date
JP2021522786A JP2021522786A (ja) 2021-09-02
JP2021522786A5 JP2021522786A5 (enExample) 2022-05-13
JP7684047B2 true JP7684047B2 (ja) 2025-05-27

Family

ID=68386875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560958A Active JP7684047B2 (ja) 2018-05-04 2019-05-03 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
JP2025082038A Pending JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025082038A Pending JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法

Country Status (8)

Country Link
US (1) US12441781B2 (enExample)
EP (1) EP3788068A4 (enExample)
JP (2) JP7684047B2 (enExample)
KR (1) KR20210028150A (enExample)
CN (4) CN110437339B (enExample)
AU (1) AU2019262590B2 (enExample)
CA (1) CA3099039A1 (enExample)
WO (1) WO2019213517A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
CN111100211B (zh) * 2019-01-30 2022-04-08 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021113577A1 (en) * 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US12459984B2 (en) * 2019-12-27 2025-11-04 National University Corporation Kobe University Cancer gene therapy drug
WO2021142476A1 (en) * 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Single-chain polypeptides
CN113321738A (zh) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
US20230141575A1 (en) * 2020-03-18 2023-05-11 City Of Hope Multivalent chemokine receptor binding complexes
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN114057889B (zh) * 2020-07-30 2023-11-10 深圳市北科生物科技有限公司 二硫键稳定的IL15-IL15Rα复合物及其应用
EP4206219A1 (en) * 2020-08-31 2023-07-05 GI Cell, Inc. Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof
KR20230104866A (ko) * 2020-09-16 2023-07-11 베이진 엘티디 인터류킨 15 작제물 및 사용 방법
CN118598977A (zh) * 2020-10-18 2024-09-06 北京志道生物科技有限公司 经修饰的il-2分子及其用途
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CA3214757A1 (en) * 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
CN116375888A (zh) * 2021-05-08 2023-07-04 上海交通大学 一种融合蛋白及其制备方法和用途
CN113817072B (zh) * 2021-10-28 2024-02-20 苏州生物医药转化工程中心 一种白细胞介素15及其受体-单克隆抗体融合蛋白的纯化贮存方法
EP4435011A4 (en) * 2021-11-15 2025-07-16 Inst Biophysics Cas FUSION PROTEIN CONSTRUCTION TAKING INTERLEUKIN 15 AS ACTIVE INGREDIENT AND USE THEREOF
WO2023160721A1 (en) * 2022-02-28 2023-08-31 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof
WO2024039973A2 (en) * 2022-08-05 2024-02-22 Staidson Biopharma Inc. Masking polypeptide, activatable novel prodrugs and methods of use thereof
KR20250135294A (ko) * 2023-02-21 2025-09-12 레메젠 코, 리미티드 암을 위한 il-15 작용제
CN118909134A (zh) * 2023-05-06 2024-11-08 北京新合睿恩生物医疗科技有限公司 IL-15融合蛋白及其mRNA序列和应用
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用
AU2023476910A1 (en) * 2023-12-19 2026-07-09 Immunelogic Therapeutics, Inc. Bifunctional fusion protein composed of il-15 and t cell co-stimulatory molecule antibody
WO2026006679A1 (en) * 2024-06-28 2026-01-02 The Regents Of The University Of California Retroviral vectors
WO2026037415A1 (zh) * 2024-08-16 2026-02-19 北京清辉联诺生物科技有限责任公司 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用
WO2026042913A1 (ko) * 2024-08-22 2026-02-26 주식회사 박셀바이오 재조합 개 인터루킨-15를 포함하는 종양에 이환된 개의 암 치료용 조성물
US20260109746A1 (en) * 2024-10-22 2026-04-23 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use
CN121949562A (zh) * 2024-10-30 2026-05-01 钱杭江医药科技(嘉兴)有限公司 一种新型蛋白复合物的二聚体化合物及其制备方法和制药用途
CN121422192A (zh) * 2025-11-20 2026-01-30 斯霈生物医药(北京)有限公司 一种序贯给药的细胞因子靶向治疗系统及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009512433A (ja) 2005-10-20 2009-03-26 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） Ｉｌ−１５ｒベータ／ガンマを介したｉｌ−１５活性の選択的かつ強力なエンハンサーとしてのｉｌ−１５ｒアルファスシドメイン、およびハイパーアゴニスト（ｉｌ１５ｒアルファスシ−ｉｌ１５）融合タンパク質
US20090123414A1 (en) 2004-12-13 2009-05-14 Cytos Biotechnology Ag Il-15 Antigen Arrays And Uses Thereof
JP2014524737A (ja) 2011-06-24 2014-09-25 サイチューン ＩＬ−１５およびＩＬ−１５ＲαＳＵＳＨＩドメインに基づいた免疫サイトカイン
WO2017079117A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
WO2018071918A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
EP2915569A1 (en) * 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10905743B2 (en) * 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
AU2016326575A1 (en) * 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123414A1 (en) 2004-12-13 2009-05-14 Cytos Biotechnology Ag Il-15 Antigen Arrays And Uses Thereof
JP2009512433A (ja) 2005-10-20 2009-03-26 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） Ｉｌ−１５ｒベータ／ガンマを介したｉｌ−１５活性の選択的かつ強力なエンハンサーとしてのｉｌ−１５ｒアルファスシドメイン、およびハイパーアゴニスト（ｉｌ１５ｒアルファスシ−ｉｌ１５）融合タンパク質
JP2014524737A (ja) 2011-06-24 2014-09-25 サイチューン ＩＬ−１５およびＩＬ−１５ＲαＳＵＳＨＩドメインに基づいた免疫サイトカイン
WO2017079117A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
WO2018071918A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF IMMUNOLOGY，2008年02月15日，VOL.180, NO.4，P2099-2106，https://doi.org/10.4049/jimmunol.180.4.2099

Also Published As

Publication number Publication date
CN112585161B (zh) 2025-05-16
AU2019262590B2 (en) 2024-09-05
CA3099039A1 (en) 2019-11-07
CN110437339A (zh) 2019-11-12
EP3788068A4 (en) 2022-01-26
JP2025124695A (ja) 2025-08-26
KR20210028150A (ko) 2021-03-11
AU2019262590A1 (en) 2020-12-03
US12441781B2 (en) 2025-10-14
US20240218047A1 (en) 2024-07-04
WO2019213517A1 (en) 2019-11-07
CN120463816A (zh) 2025-08-12
CN112585161A (zh) 2021-03-30
CN120463817A (zh) 2025-08-12
JP2021522786A (ja) 2021-09-02
CN110437339B (zh) 2021-08-13
EP3788068A1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
JP2025124695A (ja) インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
US12473337B2 (en) Homodimeric or heterodimeric interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
US20220402988A1 (en) Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
AU2015357526B2 (en) Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
US20210393692A1 (en) Compositions and methods for adoptive cell therapy for cancer
JP2021524757A (ja) 活性化可能なインターロイキン−２ポリペプチド及びその使用方法
CN108250303B (zh) 单域抗体融合蛋白及其应用
CN118451096A (zh) 异二聚体fc细胞因子及其用途
JP2024513454A (ja) キメラ抗原受容体細胞のための人工細胞死／リポーター系ポリペプチドの組合せおよびその使用
WO2022015711A1 (en) Fusion proteins of anti-pd-l1 and attenuated interferon, and compositions and therapeutic methods thereof
CA3179414A1 (en) Human immune cells genomically modified to express orthogonal receptors
US20260070957A1 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
HK40050872A (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
JP2022552786A (ja) 標的化ｅｐｈａ３及びその使用
HK40050873A (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
WO2026107319A2 (en) Car-t cell therapy of autoimmune disease-associated joint inflammation
HK40068149B (en) Universal chimeric antigen receptor expressing immune cells and method of manufacturing the same and the therapeutic use of the same
TW202017576A (zh) 生物相關之正交細胞激素／受體對

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220504

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250515

R150 Certificate of patent or registration of utility model

Ref document number: 7684047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150